Bristol-Myers rejigs local play with a new cancer drug

Bristol-Myers Squibb Co Ltd, a global biopharmaceutical company, will launch the first immuno-oncology cancer treatment product in China, aiming to become more diversified and specialized in the Chinese market, the company's top management said.

"The initial purpose of the company's strategy is to stay competitive," said Shirley Zhao, president of BMS China. "We need to become more flexible and specialized in order to meet the local demand."

Such an approach will enable the company to focus on several disease treatment fields, including the treatment of viral hepatitis and cardiovascular disease and the development of immuno-oncology and immunology science, she said.